Investing.com -- GSK (LON: GSK) on Wednesday raised its full-year earnings guidance after posting a 35% rise in ...

(Alliance News) - GSK predicted an annual outturn at the top end of guidance, BAE Systems maintained its outlook, while Aston Martin softened its profit forecast. Here is what you need to know before ...

GSK Plc reported better-than-expected profit and raised its estimates for revenue at two key divisions, including vaccines.

(Reuters) -British drugmaker GSK said on Wednesday it expects to report annual sales and profit towards the top end of its ...

Its second-quarter sales rose to 7.99 billion pounds from 7.88 billion pounds in the same period the year prior.

GSK said on Wednesday it expects to report annual sales and profit towards the top end of its forecast range, after the ...

The Federal Reserve is expected to leave interest rates unchanged at its policy meeting later on Wednesday, though it could ...

Actuate Therapeutics' elraglusib shows promise in metastatic pancreatic cancer. Upcoming FDA meeting may accelerate approval.

AbbVie, Bristol Myers Squibb and Eli Lilly appear “relatively well-positioned,” while Novartis and Roche look more at risk, ...

GSK will partner with Hengrui Pharma to develop up to 12 treatments for indications in respiratory, immunology and ...

SALES FORECAST: The U.K. pharmaceutical company is expected to report sales of 7.8 billion pounds ($10.42 billion), according to consensus estimates compiled by the company. For last year's second ...

Hengrui Pharmaceuticals Co. Ltd. is out-licensing to GSK plc its potential best-in-class phase I phosphodiesterase 3 and 4 inhibitor (HRS-9821) for treating chronic obstructive pulmonary disease along ...